Stonebridge Capital Advisors LLC Has $7.97 Million Stock Holdings in Bristol Myers Squibb Company $BMY

Stonebridge Capital Advisors LLC reduced its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 4.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 176,716 shares of the biopharmaceutical company’s stock after selling 8,939 shares during the period. Stonebridge Capital Advisors LLC’s holdings in Bristol Myers Squibb were worth $7,970,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Darwin Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb during the second quarter worth $25,000. Harbor Capital Advisors Inc. increased its holdings in Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 313 shares in the last quarter. Total Investment Management Inc. acquired a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at about $38,000. Twin Peaks Wealth Advisors LLC bought a new stake in shares of Bristol Myers Squibb in the second quarter valued at about $40,000. Finally, Mark Sheptoff Financial Planning LLC boosted its position in shares of Bristol Myers Squibb by 233.3% during the second quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 700 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on BMY. Guggenheim reissued a “buy” rating and issued a $72.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Leerink Partners lifted their price objective on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. The Goldman Sachs Group restated a “neutral” rating and set a $57.00 target price (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Piper Sandler reaffirmed an “overweight” rating and issued a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Finally, Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $52.00 to $61.00 in a research report on Monday, December 15th. Nine analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $60.71.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $62.32 on Thursday. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The business’s 50 day moving average price is $57.42 and its two-hundred day moving average price is $50.84. The company has a market cap of $126.91 billion, a PE ratio of 18.06, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). The business had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business’s revenue was up 1.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were issued a $0.63 dividend. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a dividend yield of 4.0%. The ex-dividend date was Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.